Targeted Therapies for Leigh Syndrome: Systematic Review and Steps Towards a 'Treatabolome'

Overview

Journal J Neuromuscul Dis

Publisher Sage Publications

Specialty Neurology

Date 2021 Jul 26

PMID 34308912

Citations 2

Authors

May Yung Tiet

Zhiyuan Lin

Fei Gao

Matthew James Jennings

Rita Horvath

Affiliations

Soon will be listed here.

Abstract

Background: Leigh syndrome (LS) is the most frequent paediatric clinical presentation of mitochondrial disease. The clinical phenotype of LS is highly heterogeneous. Though historically the treatment for LS is largely supportive, new treatments are on the horizon. Due to the rarity of LS, large-scale interventional studies are scarce, limiting dissemination of information of therapeutic options to the wider scientific and clinical community.

Objective: We conducted a systematic review of pharmacological therapies of LS following the guidelines for FAIR-compliant datasets.

Methods: We searched for interventional studies within Clincialtrials.gov and European Clinical trials databases. Randomised controlled trials, observational studies, case reports and case series formed part of a wider MEDLINE search.

Results: Of the 1,193 studies initially identified, 157 met our inclusion criteria, of which 104 were carried over into our final analysis. Treatments for LS included very few interventional trials using EPI-743 and cysteamine bitartrate. Wider literature searches identified case series and reports of treatments repleting glutathione stores, reduction of oxidative stress and restoration of oxidative phosphorylation.

Conclusions: Though interventional randomised controlled trials have begun for LS, the majority of evidence remains in case reports and case series for a number of treatable genes, encoding cofactors or transporter proteins of the mitochondria. Our findings will form part of the international expert-led Solve-RD efforts to assist clinicians initiating treatments in patients with treatable variants of LS.

Citing Articles

From Diabetes to Neuropathy: A Diagnostic Journey to Leigh Syndrome.

Behzadi A, Poormehr P, Saneifard H, Shakiba M Iran J Child Neurol. 2025; 19(1):113-119.

PMID: 39896705 PMC: 11781338. DOI: 10.22037/ijcn.v19i1.46085.

Personalized Medicine in Mitochondrial Health and Disease: Molecular Basis of Therapeutic Approaches Based on Nutritional Supplements and Their Analogs.

Tragni V, Primiano G, Tummolo A, Cafferati Beltrame L, La Piana G, Sgobba M Molecules. 2022; 27(11).

PMID: 35684429 PMC: 9182050. DOI: 10.3390/molecules27113494.

Use of whole genome sequencing to determine genetic basis of suspected mitochondrial disorders: cohort study.

Schon K, Horvath R, Wei W, Calabrese C, Tucci A, Ibanez K BMJ. 2021; 375:e066288.

PMID: 34732400 PMC: 8565085. DOI: 10.1136/bmj-2021-066288.

References

Quinonez S, Leber S, Martin D, Thoene J, Bedoyan J . Leigh syndrome in a girl with a novel DLD mutation causing E3 deficiency. Pediatr Neurol. 2013; 48(1):67-72. PMC: 4535688. DOI: 10.1016/j.pediatrneurol.2012.09.013. View

Castiglioni C, Verrigni D, Okuma C, Diaz A, Alvarez K, Rizza T . Pyruvate dehydrogenase deficiency presenting as isolated paroxysmal exercise induced dystonia successfully reversed with thiamine supplementation. Case report and mini-review. Eur J Paediatr Neurol. 2015; 19(5):497-503. DOI: 10.1016/j.ejpn.2015.04.008. View

Kara B, Genc H, Uyur-Yalcin E, Sakarya-Gunes A, Topcu U, Mulayim S . Pyruvate dehydrogenase-E1α deficiency presenting as recurrent acute proximal muscle weakness of upper and lower extremities in an 8-year-old boy. Neuromuscul Disord. 2016; 27(1):94-97. DOI: 10.1016/j.nmd.2016.11.001. View

Steller J, Gargus J, Gibbs L, Hasso A, Kimonis V . Mild phenotype in a male with pyruvate dehydrogenase complex deficiency associated with novel hemizygous in-frame duplication of the E1α subunit gene (PDHA1). Neuropediatrics. 2013; 45(1):56-60. DOI: 10.1055/s-0033-1341601. View

Salviati L, Trevisson E, Rodriguez Hernandez M, Casarin A, Pertegato V, Doimo M . Haploinsufficiency of COQ4 causes coenzyme Q10 deficiency. J Med Genet. 2012; 49(3):187-91. PMC: 3983946. DOI: 10.1136/jmedgenet-2011-100394. View

Pitceathly R, Keshavan N, Rahman J, Rahman S . Moving towards clinical trials for mitochondrial diseases. J Inherit Metab Dis. 2020; 44(1):22-41. PMC: 8432143. DOI: 10.1002/jimd.12281. View

Illsinger S, Korenke G, Boesch S, Nocker M, Karall D, Nuoffer J . Paroxysmal and non-paroxysmal dystonia in 3 patients with biallelic ECHS1 variants: Expanding the neurological spectrum and therapeutic approaches. Eur J Med Genet. 2020; 63(11):104046. DOI: 10.1016/j.ejmg.2020.104046. View

Joshi C, Greenberg C, Mhanni A, Salman M . Ketogenic diet in Alpers-Huttenlocher syndrome. Pediatr Neurol. 2009; 40(4):314-6. DOI: 10.1016/j.pediatrneurol.2008.10.023. View

Haack T, Jackson C, Murayama K, Kremer L, Schaller A, Kotzaeridou U . Deficiency of ECHS1 causes mitochondrial encephalopathy with cardiac involvement. Ann Clin Transl Neurol. 2015; 2(5):492-509. PMC: 4435704. DOI: 10.1002/acn3.189. View

10.

Singhi P, De Meirleir L, Lissens W, Singhi S, Saini A . Pyruvate dehydrogenase-e1α deficiency presenting as recurrent demyelination: an unusual presentation and a novel mutation. JIMD Rep. 2013; 10:107-11. PMC: 3755565. DOI: 10.1007/8904_2012_211. View

11.

Carrozzo R, Torraco A, Fiermonte G, Martinelli D, Di Nottia M, Rizza T . Riboflavin responsive mitochondrial myopathy is a new phenotype of dihydrolipoamide dehydrogenase deficiency. The chaperon-like effect of vitamin B2. Mitochondrion. 2014; 18:49-57. DOI: 10.1016/j.mito.2014.09.006. View

12.

Spruijt L, Naviaux R, McGowan K, Nyhan W, Sheean G, Haas R . Nerve conduction changes in patients with mitochondrial diseases treated with dichloroacetate. Muscle Nerve. 2001; 24(7):916-24. DOI: 10.1002/mus.1089. View

13.

Garone C, Donati M, Sacchini M, Garcia-Diaz B, Bruno C, Calvo S . Mitochondrial encephalomyopathy due to a novel mutation in ACAD9. JAMA Neurol. 2013; 70(9):1177-9. PMC: 3891824. DOI: 10.1001/jamaneurol.2013.3197. View

14.

Wexler I, Hemalatha S, McConnell J, Buist N, Dahl H, Berry S . Outcome of pyruvate dehydrogenase deficiency treated with ketogenic diets. Studies in patients with identical mutations. Neurology. 1997; 49(6):1655-61. DOI: 10.1212/wnl.49.6.1655. View

15.

Marsac C, Benelli C, Desguerre I, Diry M, Fouque F, De Meirleir L . Biochemical and genetic studies of four patients with pyruvate dehydrogenase E1 alpha deficiency. Hum Genet. 1997; 99(6):785-92. DOI: 10.1007/s004390050449. View

16.

Prasad C, Rupar T, Prasad A . Pyruvate dehydrogenase deficiency and epilepsy. Brain Dev. 2011; 33(10):856-65. DOI: 10.1016/j.braindev.2011.08.003. View

17.

Chen Z, Zhao Z, Ye Q, Chen Y, Pan X, Sun B . Mild clinical manifestation and unusual recovery upon coenzyme Q₁₀ treatment in the first Chinese Leigh syndrome pedigree with mutation m.10197 G>A. Mol Med Rep. 2014; 11(3):1956-62. DOI: 10.3892/mmr.2014.2911. View

18.

Bonnet S, Archer S, Allalunis-Turner J, Haromy A, Beaulieu C, Thompson R . A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell. 2007; 11(1):37-51. DOI: 10.1016/j.ccr.2006.10.020. View

19.

Briones P, Lopez M, De Meirleir L, Ribes A, Rodes M, Martinez-Costa C . Leigh syndrome due to pyruvate dehydrogenase E1 alpha deficiency (point mutation R263G) in a Spanish boy. J Inherit Metab Dis. 1996; 19(6):795-6. DOI: 10.1007/BF01799177. View

20.

Nebert D, Liu Z . SLC39A8 gene encoding a metal ion transporter: discovery and bench to bedside. Hum Genomics. 2019; 13(Suppl 1):51. PMC: 6744627. DOI: 10.1186/s40246-019-0233-3. View